Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease

Andrea Teixeira-Castro,1,2,3,4,* Ana Jalles,1,2,* Sofia Esteves,1,2,* Soosung Kang,3,5,6 Liliana da Silva Santos,1,2 Anabela Silva-Fernandes,1,2 Mário F. Neto,3,4 Renée M. Brielmann,3,4 Carlos Bessa,1,2 Sara Duarte-Silva,1,2 Adriana Miranda,1,2 Stéphanie Oliveira,1,2 Andreia Neves-Carvalho,1,2 João Bessa,1,2 Teresa Summaville,7 Richard B. Silverman,3,5,6 Pedro Oliveira,8 Richard I. Morimoto3,4 and Patrícia Maciel1,2

*These authors contributed equally to this work.

Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for which there is no effective treatment. Here we provide evidence that activation of serotonergic signalling is beneficial in animal models of Machado-Joseph disease. We identified citalopram, a selective serotonin reuptake inhibitor, in a small molecule screen of FDA-approved drugs that rescued neuronal dysfunction and reduced aggregation using a C. elegans model of mutant ataxin 3-induced neurotoxicity. MOD-5, the C. elegans orthologue of the serotonin transporter and cellular target of citalopram, and the serotonin receptors SER-1 and SER-4 were strong genetic modifiers of ataxin 3 neurotoxicity and necessary for therapeutic efficacy. Moreover, chronic treatment of CMVMJD135 mice with citalopram significantly reduced ataxin 3 neuronal inclusions and astrogliosis, rescued diminished body weight and strikingly ameliorated motor symptoms. These results suggest that small molecule modulation of serotonergic signalling represents a promising therapeutic target for Machado-Joseph disease.

1 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal
2 ICVS/3Bs - PT Government Associate Laboratory, Braga/Guimarães, Portugal
3 Department of Molecular Biosciences, Northwestern University, Evanston, Illinois 60208, USA
4 Rice Institute for Biomedical Research, Northwestern University, Evanston, Illinois 60208, USA
5 Department of Chemistry, Northwestern University, Evanston, Illinois 60208, USA
6 Chemistry of Life Processes Institute and Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208, USA
7 IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal
8 ICBAS-Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal

Correspondence to: Patrícia Maciel, PhD
Life and Health Sciences Research Institute (ICVS), School of Health Sciences; University of Minho, Gualtar Campus, 4710-057 Braga, Portugal
E-mail: pmaciel@ecsaude.uminho.pt

Keywords: spinocerebellar ataxia type 3; ataxin 3 aggregation; therapy; selective serotonin reuptake inhibitor, citalopram

Abbreviations: 5-HT = serotonin; SCA3 = spinocerebellar ataxia type 3; SSRI = selective serotonin reuptake inhibitor

© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Introduction

The expansion of trinucleotide CAG repeats causes hereditary adult-onset neurodegenerative disorders such as Huntington’s disease, spinobulbar muscular atrophy, dentatorubral-pallidoluysian atrophy and six forms of spinocerebellar ataxia (Ross et al., 1998). Machado-Joseph disease (or spinocerebellar ataxia type 3, SCA3), the most common dominantly inherited SCA worldwide (Schols et al., 2004), is characterized by ataxia, ophthalmoplegia and pyramidal signs, associated with dystonia, spasticity, peripheral neuropathy and amyotrophy (Coutinho and Andrade, 1978), without cognitive decline. Pathologically, there is degeneration of the deep nuclei of the cerebellum, pontine and subthalamic nuclei, substantia nigra and spinocerebellar nuclei. The genetic basis of Machado-Joseph disease is the expansion of a polyglutamine tract within the protein ataxin 3 (ATXN3) (Kawaguchi et al., 1994). When the polyglutamine tract exceeds 60 consecutive glutamines, ATXN3 becomes highly aggregation prone, leading to an imbalance in cellular proteostasis, as aggregation-associated proteotoxicity dominates over folding and clearance (Balch et al., 2008; Morimoto, 2008).

Currently there is no treatment for Machado-Joseph disease that effectively slows disease progression. Efforts to improve patient quality of life and to sustain independence address the restless legs and extrapyramidal syndromes, treatment of cramps and of the effects of fatigue (D’Abreu et al., 2010). Not yet translated to clinical practice are therapeutic strategies that include the use of small molecules or gene targeting to manipulate the concentration, conformation, and/or location of ATXN3. For example, it is known that modulating the levels of molecular chaperones Hsp70, alphaB-crystallin and Hsp104 could prevent or inhibit ATXN3 aggregation, and promote its disaggregation (Warrick et al., 2005; Robertson et al., 2010; Cushman-Nick et al., 2013). Treatment with Hsp90 inhibitors that increase chaperone expression had beneficial effects, although it failed to achieve the predicted molecular effect of chaperone induction in animal models of Machado-Joseph disease (Silva-Fernandes et al., 2014). Likewise, activation of autophagy, either genetic or pharmacological, lessened ATXN3 pathogenesis in vivo (Menzies et al., 2010; Nascimento-Ferreira et al., 2013). In rodents, reversion of the expanded polyglutamine-associated transcription down-regulation by a histone deacetylase (HDAC) inhibitor rescued ataxic symptoms (Chou et al., 2011). Dantrolene administration (targeting intracellular calcium homeostasis) improved motor performance and prevented neuronal loss (Chen et al., 2008). While silencing of ATXN3 offers potential, the impact of this type of treatment to date has not been promising in Machado-Joseph disease mice (Costa Mdo et al., 2013; Nobrega et al., 2013). For many proposed therapies, translation into clinical practice will be further limited by human safety. The traditional approach to drug discovery, which involves de novo identification and validation of new molecular targets, is costly and time-consuming, thus limiting the number of new drugs introduced into the clinic (Shim and Liu, 2014). Moreover, as the average time required for drug development continues to increase, there has been renewed interest in drug repurposing strategies (Chong and Sullivan, 2007; Shim and Liu, 2014). On the other hand, in past years, the primary cause of new drug candidate failures has been low therapeutic efficacy in clinical trials. Among the most frequently proposed reasons for this shortcoming is the lack of translation of in vitro and recombinant drug activity to therapeutic in vivo whole organism systems. As an approach to identify novel therapeutic strategies, we used Caenorhabditis elegans (C. elegans), a powerful platform to model neurodegenerative disease and for characterization of small bioactive molecules (Kaletta and Hengartner, 2006). Previously, we established a C. elegans model for Machado-Joseph disease pathogenesis in which expression of mutant ATXN3 in the nervous system led to its progressive aggregation in distinct neuronal subtypes and altered motor behaviour (Teixeira-Castro et al., 2011a). Here, we used this model to screen a library of FDA-approved small molecules, and identified compounds that rescued or ameliorated mutant ATXN3-mediated neurological dysfunction. By combining compound treatment with genetic tools, we demonstrate that modulation of serotonergic signalling by selective serotonin reuptake inhibitors (SSRIs) suppressed mutant ATXN3 aggregation and neurotoxicity in both C. elegans and mice. This reveals the utility of the approach by which safe and highly effective bioactive small molecules can be repurposed to benefit rare diseases lacking effective therapies. The finding that serotonin recapture inhibition modulates proteotoxicity may be relevant for other protein conformation disorders.

Materials and methods

Study design

The overall objective of the study was to find novel therapeutic targets for Machado-Joseph disease. The first part of this study was designed to identify novel suppressor compounds of mutant ATXN3 pathogenesis in vivo, using a hypothesis-free approach. The second aim of the study was to validate one of the identified drugs in a vertebrate model of the disease. To achieve the two goals, a small molecule screening of a FDA-approved library was conducted using a transgenic C. elegans model of the disease (Teixeira-Castro et al., 2011a). The most promising hit of the screening regarding human safety, target specificity and conservation across evolution was tested in CMVMJD135 mice (Silva-Fernandes et al., 2014). For all animal experiments, we ensured blinded outcome assessment. Experimental design was based on power analyses for optimization of sample size. C. elegans (Supplementary Table 1) and mice (Supplementary Table 2) sample size calculations were performed for each behavioural test and pathological analyses assuming a power of 0.95 and 0.8, respectively, and a significance level of $P < 0.05$. The effect size was calculated aiming for a 50% improvement. In general, we used $n = 3–4$
per genotype/treatment of C. elegans for motility assays, \( n = 8-14 \) for aggregation (with three replicates) and \( n = 4 \) for immunoblotting. For mice, we used \( n = 13-16 \) per genotype/treatment for behavioural tests, and a group size of four animals per group for quantification of ATXN3 intranuclear inclusions, assessment of astrogliosis and western blot analysis. All experiments were designed with commitment to the principles of refinement, reduction, and replacement and performed according to the FELASA guidelines to minimize discomfort, stress, and pain to the animals, with defined humane endpoints (1994).

**Nematode strains and general methods**

For a list of strains used in this work and abbreviations, see Supplementary Table 3. All the strains were backcrossed to Bristol strain N2 five to eight times. Standard methods were used for culturing and observing C. elegans, unless otherwise noted (Brenner, 1974). Nematodes were grown on nematode growth medium plates seeded with Escherichia coli OP50 strain at 20° C.

**Compounds**

All the compounds were obtained from the commercial vendors indicated below and were used without further purification. The Prestwick Chemical Library (TM) (Prestwick Chemical) used for the C. elegans screening comprised 1120 chemical and pharmacologically diverse small molecules. Other compounds used, including the 11 hits selected for validation, were reordered from a different manufacturer before repetition of experiments: 17-(allylamo)-17-demethoxygeldanamycin (17-AAG) CAS 75747-14-7 (Biomol); niosxetine hydrochloride CAS 57754-86-6 (Sigma); scoulerine CAS 6451-73-6 (Toronto Research); eburnamonine CAS 4880-88-0 (Santa Cruz); piperlongumine CAS 20069-09-4 (Biotrend); chlortetracycline hydrochloride CAS 64-72-2 (Sigma); tiapride hydrochloride CAS 51012-33-0 (Sigma); clemizole hydrochloride CAS 1163-36-6 (Sigma); metixene hydrochloride CAS 7081-40-5 (Sigma); budesonide CAS 51333-22-3 (Sigma); noscapine CAS 128-62-1 (Sigma); estrone CAS 53-16-7 (Sigma); flavoxetine CAS 56296-78-7 (Kemprotec Ltd.); zimelidine CAS 61129-30-4 (Sigma); lysergol CAS 602-85-7 (Sigma); pindolol CAS 13523-86-9 (Sigma); trazodone hydrochloride CAS 25332-39-2 (Sigma); citalopram hydrobromide CAS 59729-32-7 (Kemprotec Ltd.); escitalopram (S-citalopram) hydrobromide CAS 219861-08-2 (Kemprotec Ltd.). Citalopram used for studies in mice and vabicaserin was kindly provided by Lundbeck.

**Drug toxicity assay**

Bristol strain N2 was used to screen the Prestwick Chemical Library (TM) for compound toxicity. The assay was performed in 96-well plate format, in liquid culture (Voisine et al., 2011). Wells each contained a final volume of 60 \( \mu \)l, comprising 20–25 animals in egg stage, drug at the appropriate concentration and OP50 bacteria to a final OD_{595} of 0.6–0.8 measured in the microplate reader (Bio-Rad microplate reader 680). To obtain the age synchronized population of eggs, gravid adults were treated with alkaline hypochlorite solution (0.5 M NaOH, ~2.6% NaClO) for 7 min. The animals were then washed in M9 buffer, resuspended in S-medium to the appropriate egg number and transferred into the 96-well plate. The OP50 bacteria were grown overnight at 37°C and 150 rpm in Luria Broth (LB) media, pelleted by centrifugation, inactivated by four to six cycles of freeze/thawing, frozen at –80°C and then resuspended in S-medium supplemented with cholesterol, streptomycin, penicillin and nystatin (Sigma). Worms were grown with continuous shaking at 180 rpm at 20°C (Shel Lab) for 7 days. The compound library was prepared in 100% dimethyl sulfoxide (DMSO, Sigma) and tested at dilutions corresponding to a maximum concentration of 1% DMSO to avoid solvent-specific developmental defects and toxicity. For each compound, two final concentrations were tested (50 \( \mu \)M and 25 \( \mu \)M). C. elegans growth, survival or fecundity. The absorbance (OD_{535}) was measured daily. OP50-only (S-medium, no vehicle), DMSO 1% (vehicle) and DMSO 5% (toxic condition) controls were used.

**C. elegans assays for motility defects and aggregation**

Wild-type (WT, N2), wild-type ATXN3 (AT3WT) and mutant ATXN3 (AT3q130) animals were grown in liquid culture in a 96-well plate format, with the chemical compounds, as described above. Four-day-old animals were transferred from the 96-well plates onto an unseeded nematode growth medium plate (equilibrated at 20°C). Plates were allowed to dry for 1 h before starting the assays. Motility assays were performed at 20°C as previously described (Gidalevitz et al., 2006; Teixeira-Castro et al., 2011a). Motor behaviour assays were run in triplicates or quadruplicates (\( n = 3 \) or 4), with a total of at least 150 animals tested per genotype and/or compound. For confocal dynamic imaging and quantification of ATXN3 aggregation, live animals were immobilized with 3 mM levamisole (Sigma) and mounted on a 3% agarose pad. All images were captured on an Olympus FV1000 (Japan) or Zeiss LSM 510 (Germany) confocal microscopes, under a x 60 oil (NA = 1.35) or x 63 water (NA = 1.0) objectives. Z-series imaging was acquired for all vehicle- and compound-treated animals, using a 515/514 nm laser excitation line for yellow fluorescent protein fusion proteins. The pinhole was adjusted to 1.0 Airy unit of optical slice, and a scan was acquired every ~0.5 \( \mu \)m along the z-axis. The quantification of the aggregates was performed as previously described (Teixeira-Castro et al., 2011a, b). Three parameters were measured: area of aggregates/total area; number of aggregates/total area; and number of aggregates. Values shown are the mean (normalized to vehicle treated control) of eight or more animals per group, unless noted otherwise.

**Chemical and pharmacological classification of the hits**

Hits were manually inspected to categorize them into chemical and pharmacological classes based on MeSH tree (Medical Subject Headings; PubMed), ChEBI Ontology (Chemical Entities of Biological Interest), and ATC (Anatomical Therapeutic Chemical) fourth level classifications. The majority of the hits were sorted into heterocyclic, alkaloid, steroid,
polycyclic, and β-amino alcohol chemical classes, and further classified into neurotransmitter, anti-inflammatory, cardiovascular, anti-infective, analgesic, and hormone pharmacological classes. For a drug that has multiple therapeutic applications, all classes were equally considered. However, if a new multi-therapeutic drug shares the same structural and pharmacological class with a high scored single therapeutic compound, we considered only a single therapeutic application and clustered the new molecule into the same class. This classification allowed us simple observation of the chemical and pharmacological classes of the hits.

**C. elegans citalopram time course assays**

For time course experiments, animals were grown on nematode growth medium plates with OP50 supplemented with citalopram. OP50 cultures were prepared as described above and concentrated 10× with S-media supplemented with streptomycin, penicillin and nystatin (Sigma). Stock solutions of citalopram (2.5 mM and 0.5 mM) (Kemprotex) or vehicle (DMSO) were prepared and added to OP50 cultures to a final concentration of 25 μM or 5 μM. Plates were seeded with 200 μl of OP50-citalopram/vehicle and left at room temperature to dry for at least 3 days. Fresh plates were prepared two to three times a week to prevent drug degradation. OFF-drug effect was evaluated by treating the animals for 4 days and after that time animals were transferred to DMSO plates (vehicle), shown in Fig. 2D as AT3q130::cit OFF. During the reproductive period, animals were transferred into new fresh plates every day.

**Immunoblotting analysis**

For determination of the steady-state protein levels of ATXN3, the animals were incubated in liquid culture with the chemical compounds in a 96-well plate format as described above. Four-day-old animals were transferred from the liquid culture onto an unseeded nematode growth medium plate (equilibrated at 20°C). After 1 h of acclimation 25 individual young adult animals were picked, boiled for 15 min in sodium dodecyl sulphate (SDS) sample buffer (to destroy all the aggregates) and the resulting extracts resolved on a 10% SDS gel, as previously described (Gidalevitz et al., 2009; Teixeira-Castro et al., 2011). Immunoblots were probed with anti-ATXN3 mouse (1H9, MAB5360, Milipore; 1:1000 or 1:150) and anti-tubulin body rabbit anti-ataxin 3 serum (kindly provided by Dr Henry Morley) (1:1000). As a loading control, mouse ataxin 3 and GAPDH were used. Western blot quantifications were performed using ImageLab Software (Bio-Rad) and was set to a final concentration of 3–4 μg/μl in all experimental conditions and followed by a 22 000 g centrifugation at 37°C. After formic acid evaporation at 37°C, the pellet was dissolved in 25 μl Laemmli buffer (SDS-insoluble fraction) followed by pH adjustment with 2 M Tris-base for SDS–polyacrylamide gel electrophoresis analysis. Gels were loaded with 50 μg of the Triton X-100-soluble fraction, 40 μl of the SDS-soluble fraction and the complete SDS-insoluble fraction. Western blot analyses were performed as described above.

**Lifespan**

Assays were performed at 20°C as previously described (Morley and Morimoto, 2004). Approximately 100 hermaphrodites were cultured on each Petri dish and were transferred to fresh plates every day until the cessation of progeny production, and about every 1–3 days thereafter. Animals were scored as dead if they showed no spontaneous movement or response when prodded. Dead animals that displayed internally hatched progeny, extruded gonad or desiccation were excluded.

**Transgenic mouse model and drug administration**

CMVMJD135 mice were generated as described previously (Silva-Fernandes et al., 2014). DNA extraction, animal genotyping and CAG repeat size analyses were performed as previously described (Silva-Fernandes et al., 2010). The mean repeat size [± standard deviation (SD)] for all mice used was 130 ± 2. Age-matched and genetic background-matched wild-type animals were used as controls. Only male mice were used in this study. We administrated citalopram hydrobromide CAS 59729-32-7 (Lundbeck, Denmark) in the drinking water at two doses (8 and 13 mg/kg/day) that roughly equate to the high dosage range prescribed to human patients for depression (Cirrito et al., 2011). Treatment was initiated at 5 weeks of age, one week before the expected onset of the first neurological symptoms. The trial was ended at 34 weeks of age, according to the humane endpoints established for the non-treated CMVMJD135 mice. All animal procedures were conducted in accordance with European regulations (European Union Directive 86/609/EEC). Animal facilities and the people directly involved in animal experiments (A.T.C., S.E., A.S.F., S.D.S.) were certified by the Portuguese regulatory
entity - Direçã£o Geral de Alimentac¸ã£o e Veterina´rio. All of the protocols performed were approved by the Animal Ethics Committee of the Life and Health Sciences Research Institute, University of Minho.

**Neurochemical quantification**

CMVMJD135 and wild-type male littermate mice (n = 5–8) were sacrificed at 24 weeks of age by decapitation, their brains were rapidly removed, snap frozen in liquid nitrogen and dissected. Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels were measured in the substantia nigra, medulla oblongata and cerebellum by high performance liquid chromatography, combined with electrochemical detection (HPLC/EC), as described previously (Santos et al., 2010). Concentrations of neurotransmitters were calculated using standard curves and results were expressed in terms of 5-HT and metabolism content per amount of protein.

**Behavioural assessment**

Behavioural analysis was performed during the diurnal period in groups of five males per cage including CMVMJD135 hemizygous transgenic mice and wild-type littermates (n = 13–16 per genotype) treated with citalopram or with vehicle (water). All behavioural tests started in a presymptomatic stage (4 weeks) and were conducted until 30 or 34 weeks of age. Neurological tests and general health assessment were performed using the SHIRPA protocol, enriched with the hanging wire test. The dragging of the paws and the stride length were evaluated with footprint analysis. Motor behaviour was further assessed using the balance beam walk test (12-mm square and 17-mm round beams) and the motor swimming test. All behavioural tests were performed as previously described (Silva-Fernandes et al., 2014). Body weight was also registered for each evaluation time point.

**Immunohistochemistry and quantification of neuronal inclusions**

Thirty-four-week-old wild-type and CMVMJD135 littermate mice, vehicle- and citalopram-treated (n = 4 for each group) were deeply anaesthetized as mentioned above, transcerebrally perfused with NaCl (0.9%) and the mouse brains embedded in O.C.T. and rapidly frozen in isopentane (Sigma, CAS#878-78-4) chilled in liquid nitrogen. Slides with 30-μm thick cryostat sections were incubated with anti-ChAT according to the Lab Vision™ Ultra-Vision™ Detection kit, Thermo Scientific). The slides were ABC system (Vector Laboratories). Thirty-four-week-old wild-type and CMVMJD135 littermate mice, vehicle- and citalopram-treated (n = 4 for each group), were deeply anaesthetized as mentioned above, transcerebrally perfused with NaCl (0.9%) and the mouse brains embedded in O.C.T. and rapidly frozen in isopentane (Sigma, CAS#878-78-4) chilled in liquid nitrogen. Slides with 30-μm thick cryostat sections were incubated with anti-ChAT according to the Lab Vision™ Ultra-Vision™ Detection kit, Thermo Scientific). The slides were

**Statistical analysis**

Data were analysed through the non-parametric Mann-Whitney U-test when variables were non-continuous or when a continuous variable did not present a normal distribution (Kolmogorov-Smirnov test, P < 0.05). Continuous variables with normal distributions and with homogeneity of variance (Levene’s test) were analysed with repeated measures ANOVA for longitudinal multiple comparisons and one-way ANOVA or Student’s t-test for paired comparisons, using Tukey or Bonferroni tests for post hoc comparisons. When these two latter assumptions were not valid, an appropriate data transformation (e.g. logarithmic) was applied, and the data were reanalysed (body weight, balance beam walk test and motor swimming test). When logarithmic data transformation did not reduce the heterogeneity of variances (hanging wire test), several mathematical models were applied. In this test, the best fit model was the logarithmic and the treatment differences were analysed according the R squares of the CMVMJD135 groups, with a normal residual distribution. Statistical analysis of C. elegans survival assays was performed using the log rank (Mantel-Cox) test. All statistical analyses were performed using SPSS 20.0/22.0 (SPSS Inc.) and G-Power 3.1.9.2 (University Kiel, Germany). A critical value for significance of P < 0.05 was used throughout the study.

**Results**

A whole animal screen identifies small molecules that ameliorate mutant ataxin 3-mediated neuronal dysfunction

To identify small bioactive molecules with therapeutic value for Machado-Joseph disease, we screened a commercially available compound library, composed mainly of FDA/EMA-approved drugs, using a C. elegans model of
Machado-Joseph disease pathogenesis (AT3q130) in which mutant ATXN3 expressed in neurons caused aggregation and motility defects (Teixeira-Castro et al., 2011). The strategy, validation approach and compound safety assays are depicted in Supplementary Figs 1 and 2. In the primary screen we identified 48 compounds (Fig. 1A) that ameliorated mutant ATXN3-mediated locomotion defects, showing a percentage of effect to non-treated animals higher than 50% within a confidence interval of 95% (Supplementary Fig. 3A). The hit compounds were categorized into chemical and pharmacological classes based on MeSH tree, ChEBI Ontology, and ATC fourth level classifications. While the chemical structure classification of the hit compounds revealed marked heterogeneity, they were enriched for specific pharmacological activities, namely modulators of neurotransmission (adrenergic, serotonergic, cholinergic, dopaminergic and histaminergic), anti-infectious, cardiovascular, anti-inflammatory, analgesic and hormone-related actions (Supplementary Fig. 3B).

A representative compound for each pharmacological cluster (Table 1) was further assessed for safety (Supplementary Fig. 2B) and ability to ameliorate motility impairment of mutant ATXN3 animals (Fig. 1B). The motility of wild-type animals was not increased by any of these hit compounds, suggesting that their action is specifically targeting mutant ATXN3-mediated pathogenesis (data not shown). Next, we examined whether these compounds affected protein aggregation in neurons of AT3q130 animals in vivo, and showed that the majority also decreased mutant ATXN3 aggregation (Fig. 1C). The reduction in ATXN3 aggregation was not due to decreased steady state levels of ATXN3 protein, suggesting a mechanism more likely related to folding stability than enhanced clearance (Fig. 1D).

In summary, this C. elegans AT3q130 repurposing screen identified compounds with novel activity as suppressors of ATXN3 pathogenesis.

**Pharmacological and genetic inhibition of C. elegans SERT suppresses ATXN3 pathogenesis**

Among the largest class of compounds that suppressed mutant ATXN3-mediated pathogenesis were those that affected serotonergic neurotransmission and modulated 5-HT-mediated signalling (Fig. 1E). Of these, citalopram is a SSRI with a proven safety record that is widely used for treatment of depression (Mandrioli et al., 2012). The primary molecular target of citalopram is the 5-HT transporter (SERT, encoded by SLC6A4), which is responsible for 5-HT reuptake by serotonergic neurons (Blakely et al., 1994). This target specificity and conservation prompted us to further examine the effects of citalopram on Machado-Joseph disease pathogenesis. Treatment with citalopram caused complete rescue of mutant ATXN3-mediated neuronal dysfunction (Fig. 1E), with a dose-response profile and a derived half-maximal effective concentration (EC$_{50}$) value of 1 μM (Supplementary Fig. 4A). Citalopram exists as a racemic mixture but its effects are largely due to the S-enantiomer, escitalopram; this and other SSRIs also had beneficial effects on AT3q130 animals (Supplementary Fig. 4B). Normal behaviour and motility, development and fecundity in wild-type animals were not affected by SSRI treatment (Supplementary Fig. 4C). Importantly, citalopram treatment significantly reduced mutant ATXN3 aggregation in C. elegans neurons (Fig. 2A), and increased ATXN3 solubility (Fig. 2B), as assessed by biochemical fractionation (Koch et al., 2011), without affecting the overall level of protein (Fig. 2C).

On continuous exposure to citalopram, the survival of AT3q130 animals was rescued (Supplementary Fig. 4D and E) and their neuronal dysfunction was restored through to Day 14 of age (Fig. 2D). This beneficial effect declined when citalopram was withdrawn, and neurotoxicity returned after 3-4 days OFF treatment (AT3q130:cat OFF, Fig. 2D). Maximum protection required early treatment (from the egg stage through to Day 4 of adulthood) (Fig. 2E); moreover, the extent of drug exposure period was critical, as 2 days of treatment were insufficient to exert beneficial effects (Fig. 2F).

In C. elegans, there is one 5-HT transporter orthologue of the vertebrate SERT, MOD-5 (Ranganathan et al., 2001). To confirm the beneficial effect of pharmacological inhibition of serotonin reuptake, we showed that genetic ablation of MOD-5 rescued mutant ATXN3-mediated motor dysfunction and aggregation in C. elegans (Fig. 2G). Pharmacogenetic analysis also supported MOD-5 as a cellular target of citalopram in the nematode, as drug treatment did not further ameliorate mutant ATXN3-mediated pathogenesis in the absence of MOD-5. In contrast, estrone (a steroid hormone) was able to further reduce the motility impairment of mod-5; AT3q130 animals (Fig. 2G), which is consistent with independent modes of action for these two compounds.

The role of 5-HT receptors was examined using pharmacological and pharmacogenetic approaches (Fig. 3A). Activation of postsynaptic 5-HT receptors by the 5-HT2C receptor (HTR2C) agonist vabicaserin (Dunlop et al., 2011) and stimulation of the presynaptic 5-HT autoreceptors by buspirone (Takei et al., 2005), dihydroergotamine (Villalon et al., 2003) (Fig. 3B), lysergol (Pertz et al., 1999) or pindolol (Corradetti et al., 1998) (Fig. 1D) ameliorated mutant ATXN3-mediated motor dysfunction. Consistent with this, genetic ablation of the 5-HT postsynaptic G-protein coupled receptor SER-1 (Hamdan et al., 1999) enhanced AT3q130 aggregation and locomotion defects (Fig. 3C). Likewise, the effect of citalopram was also dependent on these receptors. Additionally, ablation of the SER-4 (Olde and McCombie, 1997) autoreceptor, which by eliminating the negative feedback likely increases 5-HT availability, restored locomotion and reduced ATXN3 aggregation in vivo (Fig. 3D). Taken together, these results support the idea that pharmacological and genetic inhibition of MOD-5 restores motility and suppresses aggregation of AT3q130 through modulation of 5HTR activity.
Figure 1 Identification of small-molecule suppressors of ATXN3 pathogenesis. (A) Graphical representation of the results of the C. elegans-based screening in which we assessed a subset of 599 compounds of the Prestwick Chemical library. Black lines represent the mean percentage of animals with locomotion impairment for untreated AT3q130, AT3WT and wild-type animals. Grey dots show the mean of percentage of locomotion impaired AT3q130 animals upon treatment for each compound. The red line represents the assay cut-off to a minimum of 50% of effect in animals’ motor behaviour. The red dot represents the percentage of locomotion impaired AT3q130 animals upon citalopram treatment, as obtained in the primary screen. (B) Motility analysis of AT3q130 animals treated with the top 11 hit compounds found in the screen (n = 4, ± SD). *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). (C) Quantification of AT3q130 aggregation by confocal imaging and fluorescence intensity (n ≥ 10, ± SD). *P < 0.05, **P < 0.01, ***P < 0.001 (ANOVA, Bonferroni’s test). (D) Human ATXN3 expression in AT3q130 animals treated with the top hit compounds (n = 4–6 ± SEM). *P < 0.05 (Student’s t-test). (E) Motility analysis of AT3q130 animals treated with compounds targeting serotonergic neurotransmission found in the screen (n = 4, ± SD). *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). WT = wild-type; AT3WT = wild-type ATXN3 expressing animals; AT3q130 = mutant ATXN3 expressing animals.
<table>
<thead>
<tr>
<th>Cluster</th>
<th>Pharmacological action</th>
<th>Drug</th>
<th>Structure</th>
<th>Number of hit compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Neurotransmitter Adrenergic</td>
<td>Nisoxetine HCl</td>
<td><img src="image" alt="Nisoxetine HCl" /></td>
<td>8</td>
</tr>
<tr>
<td>2</td>
<td>Neurotransmitter Serotonergic</td>
<td>Scoulerine</td>
<td><img src="image" alt="Scoulerine" /></td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>Neurotransmitter Cholinergic</td>
<td>Metixene HCl</td>
<td><img src="image" alt="Metixene HCl" /></td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>Neurotransmitter Dopaminergic</td>
<td>Tiapride HCl</td>
<td><img src="image" alt="Tiapride HCl" /></td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>Neurotransmitter Histaminergic</td>
<td>Clemizole HCl</td>
<td><img src="image" alt="Clemizole HCl" /></td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>Anti-inflammatory</td>
<td>Budesonide</td>
<td><img src="image" alt="Budesonide" /></td>
<td>5</td>
</tr>
<tr>
<td>7</td>
<td>Cardiovascular</td>
<td>Eburnamonine</td>
<td><img src="image" alt="Eburnamonine" /></td>
<td>5</td>
</tr>
<tr>
<td>8</td>
<td>Hormones/Hormone substituents</td>
<td>Estrone</td>
<td><img src="image" alt="Estrone" /></td>
<td>4</td>
</tr>
<tr>
<td>9</td>
<td>Analgesic</td>
<td>Noscapine</td>
<td><img src="image" alt="Noscapine" /></td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>Anti-infective</td>
<td>Chlortetracycline HCl</td>
<td><img src="image" alt="Chlortetracycline HCl" /></td>
<td>8</td>
</tr>
<tr>
<td>11</td>
<td>Etc.</td>
<td>Piperlongumine</td>
<td><img src="image" alt="Piperlongumine" /></td>
<td>9</td>
</tr>
</tbody>
</table>

*HCl = hydrochloride.
Citalopram treatment improves motor balance and coordination of CMVMJD135 mice

To further investigate the therapeutic potential of citalopram, we used a transgenic mouse model of Machado-Joseph disease, CMVMJD135, that displays progressive Machado-Joseph disease-like motor decline and neuropathology, including ATXN3-positive intranuclear inclusions in the CNS (Silva-Fernandes et al., 2014). Although CMVMJD135 mice showed no changes in baseline 5-HT levels measured by HPLC (Fig. 4), oral administration of citalopram (8 mg/kg) to these animals (study design; Fig. 5A) prevented their decreased body weight gain (Fig. 5B) and had significant beneficial effects on the motor phenotype. While there was only marginal
Figure 3  Serotonergic signalling improves ATXN3 pathogenesis in a G-protein coupled receptor-dependent manner. (A) Schematic of a serotonergic synapse showing that 5-HT is synthesized and released into the synaptic cleft, where it activates postsynaptic 5-HT receptors. Vabicaserin may activate the regulatory signalling coupled with SER-1. Pindolol, lysergol and DHE probably antagonize the 5-HT autoreceptor SER-4, whereas the 5-HT1A receptor agonist buspirone may desensitize the receptor, shutting down the stop production signal mediated by 5-HT autoreceptors in presynaptic neurons. (B) Motor behaviour of AT3q130 animals treated with vabicaserin, buspirone and dihydroergotamine. (C) Motility defects and aggregation load of AT3q130 animals in a ser-1 genetic background, with and without cit, S-citalopram and estrone treatments. (D) Motility performance and mutant ATXN3 aggregation phenotypes of AT3q130 animals in the absence of SER-4. For motor behaviour assays: (n = 3–4, ± SD), *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test). For aggregate quantification: (n ≥ 12, ± SD), *p < 0.05, **p < 0.01, ***p < 0.001 (ANOVA, Bonferroni’s test). DHE = dihydroergotamine; DMSO = dimethyl sulphoxide; cit = citalopram; S-cit = S-citalopram; fluox = fluoxetine.
improvement in the dragging of the paws (Supplementary Fig. 5A) and limited effects on exploratory activity (Supplementary Fig. 5B), grip strength (Supplementary Fig. 5C) and hindlimb tonus (Supplementary Fig. 5D), citalopram treatment restored stride length to wild-type levels at advanced stages of the trial (Fig. 5C). Moreover, treated animals showed reduced tremors (Fig. 5D), reduced limb clasping (Fig. 5E), and improved gait quality (Fig. 5F).

Citalopram treatment also resulted in a striking improvement in balance and motor coordination as compared to vehicle-treated CMVMJD135 mice. In the balance beam walk test, we observed major improvements in the 12 mm square beam from 20 to 34 weeks of age (Fig. 6A and Supplementary Video 1) and also in a wider (17 mm) round beam (Supplementary Fig. 5E). The most remarkable benefits of citalopram were observed in the motor swimming test (Fig. 6B), since at many time points and until quite late in the trial citalopram treated animals were indistinguishable from wild-type (Supplementary Video 2).

Overall, these results demonstrate that citalopram can reduce the impairment in motor coordination of the Machado-Joseph disease mouse, with less benefit on strength, suggesting effects at the level of the brainstem, midbrain or cerebellum, rather than on spinocerebellar tracts and muscle innervation. Treatment also significantly delayed disease progression in mice.

Citalopram treated wild-type mice behaved similarly to their untreated littermates, confirming the specificity of the effect (Supplementary Fig. 6). Moreover, CMVMJD135 mice treated with a dosage of 13 mg/kg showed more limited improvements when compared to vehicle-treated controls in all paradigms mentioned above (Supplementary Fig. 7).

The analysis of brain tissue from CMVMJD135 mice showed that citalopram treatment (8 mg/kg) mitigated reactive astrogliosis (Fig. 6C) and decreased ATXN3 intranuclear inclusions in the brainstem (Fig. 6D), analogous to the reduction of neuronal aggregates in C. elegans. This reduction was observed in the pontine nuclei, reticulotegmental nuclei of pons and facial motor nuclei of CMVMJD135-treated mice when compared to their vehicle-treated counterparts (Fig. 6D); the impact of citalopram was less marked in the lateral reticular nuclei. This reduced ATXN3 aggregation did not correspond to lower levels of ATXN3 protein levels in the brainstem (Fig. 6E), suggesting that the effect of citalopram in mice is similar to that in C. elegans, affecting folding and stability of ATXN3 rather than clearance of the mutant protein. Citalopram treatment also had neuroprotective effects, rescuing loss of ChAT-positive motor neurons in the facial motor nuclei (Fig. 7A). The same trend was observed for motor neurons of the ventral horn of the lumbar spinal cord (Fig. 7B), albeit without statistical significance, in agreement with the observed phenotypic effects upon treatment. The mild reduction in Calbindin D28-K-positive cells seen in the cerebellar cortex of CMVMJD135 mice was also circumvented by citalopram treatment (Fig. 7C).
Discussion

In this study we describe a small molecule screen using a collection of FDA/EMA-approved drugs to identify modulators of neuronal dysfunction in transgenic *C. elegans* expressing mutant ATXN3. By using two model systems, we combined the ease and speed of screening in *C. elegans*, the ability to use genetics and selected small molecule agonists and antagonists of receptors and transporters to validate pathways, and the relevance of subsequent confirmation in a vertebrate model of Machado-Joseph disease. This led to the identification of neuroactive compounds, among which modulators of the serotonergic pathway that strongly suppressed Machado-Joseph disease pathogenesis *in vivo*. In support of this screening strategy, many of the suppressors of ATXN3 pathogenesis identified in our study have been shown to be effective in other neurodegenerative disorders, including Parkinson's and Alzheimer's disease, and also in Machado-Joseph disease (Clarke *et al.*, 1966; Perenyi *et al.*, 1985; Kanai *et al.*, 1986). 

Figure 5 Impact of citalopram treatment at 8 mg/kg on the neurological deficits of CMVMJD135 mice. (A) Schematic representation of the preclinical therapeutic trial. Significant differences observed between vehicle (n = 13) and citalopram-treated CMVMJD135 mice (n = 16) in (B) body weight (P = 0.001, 20–34 weeks) and (C) stride length (P = 0.015, 30 weeks). (D) Tremors, (E) limb clasping and (F) gait were evaluated from 18 to 34 weeks of age with phenotype amelioration from 22 to 34 weeks of age. (n = 13–16, ± SD), *p* < 0.05, ***p* < 0.01 and ****p < 0.001 (Mann-Whitney U-test for non-parametric variables and ANOVA, Tukey correction for continuous variables). cit = citalopram.
Figure 6  Citalopram treatment ameliorates balance and motor coordination and suppresses mutant ATXN3 aggregation in Machado-Joseph disease mice. Significant differences observed between vehicle (n = 13) and citalopram-treated CMVMJD135 mice (n = 16) in the (A) square beam (P < 0.001, 20–34 weeks) and (B) motor swimming (P < 0.001, 14–34 weeks) tests. (C) Immunohistochemistry and quantification of GFAP-positive cells per area in substantia nigra from wild-type, vehicle- and citalopram-treated CMVMJD135 mice (n = 5 per group, 34 weeks). (D) Neuronal inclusions in the pontine nuclei, reticulotegmental nuclei of the pons, facial motor nucleus and lateral reticular nucleus of vehicle and citalopram-treated CMVMJD135 mice (n = 4, 34 weeks). (E) Brainstem immunoblots and quantification of total human ATXN3 protein from vehicle and citalopram-treated CMVMJD135 mice (n = 5, 34 weeks). Data presented as mean ± SEM, *P < 0.05 and **P < 0.01 [ANOVA, Tukey correction (A and B) and one-way ANOVA (C–E)]. Scale bars = 20 μm. cit = citalopram; WT = wild-type; SN = substantia nigra; PN = pontine nuclei; RtTg = reticulotegmental nuclei of pons; 7N = facial motor nuclei; LRt = lateral reticular nuclei.
A more in-depth understanding of the mechanism of action of these suppressors of expanded ATXN3 toxicity and their ability to modulate aggregation offers new opportunities for small-molecule therapeutics for Machado-Joseph disease and other protein conformational diseases.

Citalopram and other SSRIs suppressed Machado-Joseph disease pathogenesis in the *C. elegans* and mouse models, showing beneficial effects on motility/coordination, aggregation of mutant ATXN3, and disease progression. MOD-5 (and SERT) inhibition by citalopram likely results in increased extracellular 5-HT levels and enhanced serotonergic neurotransmission that can elicit 5-HT dependent effects on neuronal activities, adaptation (Blier and de Montigny, 1999; El Mansari *et al.*, 2005; Schilstrom *et al.*, 2011), and remodelling (Musazzi *et al.*, 2010; Bessa *et al.*, 2013). Indeed, ablation of the postsynaptic receptor SER-1 (Hamdan *et al.*, 1999), which is pharmacologically similar to the mammalian 5-HT2 receptor, aggravated ATXN3 pathogenesis. The beneficial action of citalopram required SER-1, suggesting that the downstream effects of this drug are mediated by signalling cascades involving this receptor. Furthermore, ablation of SER-4, which shares similarity to vertebrates’ 5-HT1 autoreceptors, rescued motor neuron dysfunction and reduced ATXN3 aggregation *in vivo*.

The therapeutic effects of SSRIs for amelioration of mutant ATXN3-mediated neurotoxicity in both *C. elegans* and mice required chronic treatment; likewise, citalopram prolonged treatment is necessary in depression (Blier and de Montigny, 1999). Such SSRI treatment modalities result in 5-HT1A autoreceptor desensitization (Blier and De...
Montigny, 1983; Lanfumey et al., 2008), which inactivates the negative feedback mechanism taking place in presynaptic neurons, thereby increasing 5-HT availability and activating postsynaptic receptors (Lanfumey and Hamon, 2004). Pindolol, a β-adrenergic receptor partial agonist with 5-HT1A receptor antagonist properties, when combined with SSRIs, results in a significant decrease in time to first response compared with SSRIs alone. Moreover, a faster desensitization of 5-HT1A autoreceptors by a direct agonist (e.g. buspirone) may also accelerate the therapeutic efficacy of SSRIs (Blier and Ward, 2003). Consistently, targeting 5-HT autoreceptors by chronic treatment ameliorated mutant ATXN3-mediated pathogenesis in C. elegans. Serotonin receptors in nematodes and mammals, while homologous, may not be functionally identical (Komuniecki et al., 2004); therefore, it would be important to identify the specific 5-HT receptors required for citalopram’s effect on toxicity and aggregation of mutant ATXN3 in mice.

In Huntingdon’s disease mouse models, SSRI treatment resulted in striatal and memory preservation and extended survival (Lauterbach, 2013). Citalopram has also been shown to be beneficial in models of Alzheimer’s disease and in healthy human volunteers by reducing amyloid-β in the CSF (Cirrito et al., 2011; Sheline et al., 2014). The need for chronic and early symptomatic treatment in Machado-Joseph disease suggests a neuroprotective mechanism rather than immediate effects on signalling cascades (Sheline et al., 2014) or correction of an imbalance of 5-HT in Machado-Joseph disease mice. Moreover, the effect of citalopram and MOD-5 inactivation on aggregation ATXN3 is consistent with an impact of serotonergic neurotransmission on the rebalance of proteostasis state of the organism. Indeed, it has been recently described that the release of serotonin from neurons signals to distal tissues the activation of protective mechanisms to prevent proteotoxicity (Tatum et al., 2015).

Comparing the effects obtained with citalopram with those described in the literature for other molecules with positive effect in Machado-Joseph disease models, this SSRI appears to have a higher therapeutic efficacy. From our own work, when we compare the current results with the previous findings for the Hsp90 inhibitor 17-DMAG (Silva-own work, when we compare the current results with the appearance to have a higher therapeutic efficacy. From our positive effect in Machado-Joseph disease models, this SSRI those described in the literature for other molecules with effect of 17-DMAG in this test was 33%, and that of citalopram was 79%. The difference in performance between the treated groups (normalized to the respective non-treated groups) in the two experiments was statistically significant at this age (P = 0.018).

In conclusion, the efficacy of citalopram in suppression of ATXN3 pathogenesis in two disease models, as well as its safety record of being widely used in depression patients, prompts us to suggest this drug for clinical trials in patients with Machado-Joseph disease.

Acknowledgements

We are grateful to members of the Maciel and Morimoto laboratories for sharing reagents, for critical analysis of the data and discussions on the manuscript. We also thank Lundbeck for providing citalopram for the preclinical trial in mice and Drs Karina Fog and Soren Moller for discussions on experimental planning and data. We are grateful to Dr Veena Prahlad and Dr Michael Ailion for comments on C. elegans pharmacogenetic experiments. Thanks to the Caenorhabditis Genetics Center (CGC), which is funded by the National Institutes of Health – National Center for Research Resources, for some of the nematode strains.

Funding

This work was supported by Fundação para a Ciência e Tecnologia (FCT) and COMPETE through the projects [PTDC/SAU-GMG/112617/2009] (to P.M.) and [EXPL/ BIM-MEC/0239/2012] (to A.T.C.), by National Ataxia foundation (to P.M.), by Ataxia UK (to P.M.), by National Institutes of Health (NIH) [GM038109, GM081192, AG026647, and NS047331] (to R.I.M.), by The Chicago Biomedical Consortium (to R.I.M.) and by the Ellison Medical Foundation (to R.I.M.). A.T.C., A.J., S.E., L.S.S., C.B., S.D.S., A.S.F. and A.N.C. were supported by the FCT individual fellowships SFRH/BPD/91562/2012 and SFRH/BPD/78388/2011, SFRH/BPD/91562/2012 and SFRH/BPD/51059/2010, respectively. FCT fellowships are co-financed by POPH, QREN, Governo da República Portuguesa and EU/FSE.

Supplementary material

Supplementary material is available at Brain online.

References


Blenner S. The genetics of *Caenorhabditis elegans*. Genetics 1974; 77: 71–94.


